OncLive TV

Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Ulka N. Vaishampayan, MBBS, FAB, discusses the expanding role of TKI/immunotherapy combinations in metastatic renal cell carcinoma.

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

Maurie Markman, MD, discusses the utility of PARP inhibitors in ovarian cancer.

James B. Yu, MD, MHS, discusses the utility of radiation in men with prostate cancer.

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

Weijing Sun, MD, FACP, discusses the ​use of ramucirumab plus paclitaxel in metastatic gastric cancer.

Michael J. Cavnar, MD, discusses the management of patients with liver metastas​es in colorectal cancer.

John A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses unmet needs in triple-class refractory multiple myeloma.

Jeffrey S. Weber, MD, PhD, discusses the evolution of the treatment paradigm in melanoma.

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.

Monica L. Baskin, PhD, discusses the roles of race and early screening in prostate cancer.

Brian T. Hill, MD, PhD, discusses the approval of brexucabtagene autoleucel  in mantle cell lymphoma.

Ira Braunschweig, MD, discusses factors to consider when selecting between autologous stem cell transplant, allogeneic stem cell transplant, and CAR T-cell therapy in diffuse large B-cell lymphoma.

Ramaprasad Srinivasan, MD, PhD, discusses the challenges of developing new therapies to treat patients with rare renal cell carcinoma subtypes.

Jason J. Luke, MD, FACP, discusses the role of targeted therapy in melanoma.

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.

Naveen Pemmaraju, MD, discusses current treatment strategies in blastic plasmacytoid dendritic cell neoplasm.

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

William D. Tap, MD, discusses future research efforts in sarcoma.

John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.

Tanios S. Bekaii-Saab, MD, FACP, discusses the future of telemedicine in colorectal cancer.

Himisha Beltran, MD, discusses the need to identify non–androgen receptor targets in prostate cancer.